-
Article
Open AccessImpact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study
In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib d...
-
Article
Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis
Neoadjuvant immunotherapy (nIO) has emerged as a treatment option for stage II–III triple-negative breast cancer (TNBC). While randomised clinical trials (RCTs) demonstrated pathological complete response rate...
-
Chapter
Adjuvant Therapy
During treatment for localized breast cancer, adjuvant systemic therapy allowed a relevant improvement in outcomes, reducing recurrence and improving survival. Chemotherapy, anti-HER2 therapy, and endocrine th...
-
Chapter
Genomic Tests
Classically, clinical and pathological features have been used to assess the prognosis of breast cancer patients. However, these features alone are not accurate, especially for hormonal receptor (HR)-positive ...
-
Chapter
Neoadjuvant Systemic Therapy
Neoadjuvant systemic therapy (NST) is widely embraced as the initial treatment primarily to locally advanced breast cancer and selected cases of early-stage breast cancer in order to enable a breast and axilla...
-
Article
Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting
Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m2 of pa...
-
Article
Management of Colon Cancer and Liver Metastases: Is There a Role for Molecularly Targeted Agents?
Recent advances in caring for metastatic colorectal patients have yielded significantly longer survival times. When metastasis is confined to one or even two organs and is amenable to resection, 20–40 % of pat...
